Artificial intelligence continues to transform biomedical research and healthcare delivery. Imagene AI secured $23 million to advance multimodal digital pathology foundation models, combining histopathology images with molecular and clinical data to enable personalized clinical trials. Simultaneously, Healx partnered with SCI Ventures to accelerate drug discovery for spinal cord injury through AI-powered target identification and repurposing, aiming to shorten development timelines for therapies addressing debilitating neurotraumas. Adaptive Biotechnologies enhanced clinical adoption of its ClonoSeq minimal residual disease assay by integrating it into Flatiron Health’s electronic medical record platform, streamlining workflows for community oncologists. These advances illustrate the expanding role of AI in precision medicine and immunotherapy research, offering improved diagnostics, therapeutic development, and patient management.